ArticleFrontiers in oncology2026
A rare case of Lung adenocarcinoma complicated with leptomeningeal and brain parenchymal metastasis: case report and review of the literature.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastasis (BM) represents a severe and common complication of advanced lung cancer, which is clinically categorized into brain parenchymal metastasis (BPM) and leptomeningeal metastasis (LM), with LM being the predominant subtype of meningeal involvement. In clinical practice, the concurrent occurrence of both parenchymal brain and leptomeningeal metastases in a single patient remains rare. Here, we report a case of an epidermal growth factor receptor (EGFR)-mutant NSCLC patient with simultaneous BPM and LM, along with a review of current research progress on the treatment of BM. The patient had previously undergone surgery and targeted therapy, and subsequently developed bone metastases, LM and BPM. After receiving ventriculoperitoneal shunting, intrathecal chemotherapy via an Ommaya reservoir, and resection of the brain metastatic lesion, the patient's condition was effectively controlled. This case suggests that some EGFR-mutant NSCLC patients may still experience CNS progression during EGFR-tyrosine kinase inhibitor (TKI) therapy. Moreover, local therapy (surgery) combined with intrathecal chemotherapy may improve quality of life and prolong survival, thus representing a feasible treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.